• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Imara to Webcast Conference Call of Second Quarter 2021 Financial Results and Business Highlights

    7/30/21 7:00:00 AM ET
    $IMRA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $IMRA alert in real time by email

    BOSTON, July 30, 2021 (GLOBE NEWSWIRE) -- Imara Inc. (NASDAQ:IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients suffering from rare inherited genetic disorders of hemoglobin, today announced that the company will host a conference call and live webcast on Friday, August 6, 2021, at 8:30 a.m. ET to discuss its financial results for the quarter ended June 30, 2021 and review recent business highlights.

    A live webcast will be available under "Events and Presentations" in the Investors section of the company's website. The conference call can be accessed by dialing 1 (833) 519-1307 (U.S. domestic) or +1 (914) 800-3873 (international) and referring to conference ID 6499377. A replay of the webcast will be archived on the Imara website following the presentation.

    About Imara

    Imara Inc. is a clinical-stage biotechnology company dedicated to developing and commercializing novel therapeutics to treat patients suffering from rare inherited genetic disorders of hemoglobin. Imara is currently advancing IMR-687, a highly selective, potent small molecule inhibitor of PDE9 that is an oral, once-a-day, potentially disease-modifying treatment for sickle cell disease and beta-thalassemia. IMR-687 is being designed to have a multimodal mechanism of action that acts on red blood cells, white blood cells, adhesion mediators and other cell types. For more information, please visit www.imaratx.com.

    Media Contact:

    Marin Bergman

    Ten Bridge Communications

    818-516-2746

    [email protected]

    Investor Contact:

    Michael Gray

    617-835-4061

    [email protected]



    Primary Logo

    Get the next $IMRA alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $IMRA

    DatePrice TargetRatingAnalyst
    1/6/2022$12.00 → $4.00Equal-Weight
    Morgan Stanley
    11/30/2021$10.00Buy
    HC Wainwright & Co.
    8/11/2021$33.00 → $12.00Overweight → Equal-Weight
    Morgan Stanley
    More analyst ratings

    $IMRA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • 5am Partners Vi, Llc sold $12,292,500 worth of shares (825,000 units at $14.90) (SEC Form 4)

      4 - Enliven Therapeutics, Inc. (0001672619) (Issuer)

      2/16/24 4:15:31 PM ET
      $IMRA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Phillips Andrew John

      4 - Enliven Therapeutics, Inc. (0001672619) (Issuer)

      2/15/24 9:04:08 PM ET
      $IMRA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Patel Anish

      4 - Enliven Therapeutics, Inc. (0001672619) (Issuer)

      2/15/24 9:02:21 PM ET
      $IMRA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $IMRA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Morgan Stanley reiterated coverage on Imara with a new price target

      Morgan Stanley reiterated coverage of Imara with a rating of Equal-Weight and set a new price target of $4.00 from $12.00 previously

      1/6/22 10:34:33 AM ET
      $IMRA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • HC Wainwright & Co. initiated coverage on Imara with a new price target

      HC Wainwright & Co. initiated coverage of Imara with a rating of Buy and set a new price target of $10.00

      11/30/21 7:23:31 AM ET
      $IMRA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Imara downgraded by Morgan Stanley with a new price target

      Morgan Stanley downgraded Imara from Overweight to Equal-Weight and set a new price target of $12.00 from $33.00 previously

      8/11/21 6:17:27 AM ET
      $IMRA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $IMRA
    Financials

    Live finance-specific insights

    See more
    • Enliven Therapeutics and Imara Announce Merger Agreement

      Merger to create Nasdaq-listed, clinical-stage biopharmaceutical company focused on advancing Enliven's portfolio of precision oncology programsCombined company is expected to have a cash balance of approximately $300 million at close, which is expected to provide cash runway through multiple clinical milestones and into early 2026Planned concurrent financing of approximately $165 million co-led by new investors Fairmount and Venrock Healthcare Capital Partners, with participation from additional new investors including Fidelity Management & Research Company, RA Capital Management, Frazier Life Sciences and Commodore Capital and support from all existing Enliven investorsCompanies to host co

      10/13/22 4:35:22 PM ET
      $IMRA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Imara Reports Full Year 2021 Financial Results and Business Highlights

      Completed enrollment in Phase 2b sickle cell disease and beta-thalassemia trials with tovinontrine (IMR-687); expect to report both interim datasets in first week of April 2022 Changed primary endpoint of Ardent Phase 2b trial in sickle cell disease to reductions in annualized rate of VOCs at written request of the FDA Added clinical indication for tovinontrine to include the treatment of HFpEF; anticipate first subject dosing in Phase 2 trial in second quarter of 2022 Expanded pipeline with addition of IMR-261, an oral, clinic-ready Nrf2 activator with potential indications in hemoglobin and iron overload disorders Company to host conference call and live webcast today at 8:30 AM ET BO

      3/15/22 7:00:00 AM ET
      $IMRA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Imara to Webcast Conference Call of Full Year 2021 Financial Results and Business Highlights

      BOSTON, March 08, 2022 (GLOBE NEWSWIRE) -- Imara Inc. (NASDAQ:IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients suffering from rare hemoglobin disorders and other serious diseases, today announced that the company will host a conference call and live webcast on Tuesday, March 15, at 8:30 a.m. ET to discuss its financial results for the year ended December 31, 2021 and review recent business highlights. A live webcast will be available under "Events and Presentations" in the Investors section of the company's website. The conference call can be accessed by dialing +1 (833) 519-1307 (U.S. domestic) or (914) 800

      3/8/22 7:00:00 AM ET
      $IMRA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $IMRA
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Imara Announces Stockholder Approval of Merger With Enliven

      -- Combined Company to Trade on Nasdaq Under Ticker "ELVN" ---- Imara Announces 1-for-4 Reverse Stock Split of Common Stock -- BROOKLINE, Mass., Feb. 22, 2023 (GLOBE NEWSWIRE) -- Imara Inc. (NASDAQ:IMRA) today announced the results of the special meeting of its stockholders held on February 22, 2023. At the special meeting, Imara's stockholders voted in favor of all proposals, including the proposal to approve the issuance of shares of Imara's common stock to the stockholders of Enliven Therapeutics, Inc. ("Enliven") pursuant to the terms of the Agreement and Plan of Merger, dated as of October 13, 2022, pursuant to which a direct, wholly-owned subsidiary of Imara will merge with and into

      2/22/23 4:01:00 PM ET
      $IMRA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Lifshitz Law PLLC Announces Investigations of IMRA, AGFS, USER, and PEBO

      NEW YORK, NY / ACCESSWIRE / November 23, 2022 / Lifshitz Law PLLC:Imara Inc. (NASDAQ:IMRA)Lifshitz Law PLLC announces an investigation into possible breach of fiduciary duties in connection with the merger of IMRA and Enliven Therapeutics, Inc.If you are an IMRA investor, and would like additional information about our investigation, please complete the Information Request Form or contact Joshua Lifshitz, Esq. by telephone at (516)493-9780 or email at [email protected] Solutions, Inc. (NASDAQ:AGFS)Lifshitz Law PLLC announces an investigation into possible breach of fiduciary duties in connection with the sale of AGFS to Paine Schwartz Partners for $3.00 per share in cash.If you a

      11/23/22 7:48:00 PM ET
      $AGFS
      $IMRA
      $PEBO
      $USER
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Major Banks
      Finance
    • Enliven Therapeutics and Imara Announce Merger Agreement

      Merger to create Nasdaq-listed, clinical-stage biopharmaceutical company focused on advancing Enliven's portfolio of precision oncology programsCombined company is expected to have a cash balance of approximately $300 million at close, which is expected to provide cash runway through multiple clinical milestones and into early 2026Planned concurrent financing of approximately $165 million co-led by new investors Fairmount and Venrock Healthcare Capital Partners, with participation from additional new investors including Fidelity Management & Research Company, RA Capital Management, Frazier Life Sciences and Commodore Capital and support from all existing Enliven investorsCompanies to host co

      10/13/22 4:35:22 PM ET
      $IMRA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $IMRA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13D/A filed by IMARA Inc. (Amendment)

      SC 13D/A - Enliven Therapeutics, Inc. (0001672619) (Subject)

      2/16/24 4:15:28 PM ET
      $IMRA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by IMARA Inc. (Amendment)

      SC 13G/A - Enliven Therapeutics, Inc. (0001672619) (Subject)

      2/14/24 8:53:21 PM ET
      $IMRA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by IMARA Inc. (Amendment)

      SC 13G/A - Enliven Therapeutics, Inc. (0001672619) (Subject)

      2/14/24 4:58:16 PM ET
      $IMRA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $IMRA
    SEC Filings

    See more
    • SEC Form 144 filed by IMARA Inc.

      144 - Enliven Therapeutics, Inc. (0001672619) (Subject)

      2/15/24 5:04:57 PM ET
      $IMRA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 144 filed by IMARA Inc.

      144 - Enliven Therapeutics, Inc. (0001672619) (Subject)

      12/20/23 6:06:54 PM ET
      $IMRA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 144 filed by IMARA Inc.

      144 - Enliven Therapeutics, Inc. (0001672619) (Subject)

      12/19/23 5:27:50 PM ET
      $IMRA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $IMRA
    Leadership Updates

    Live Leadership Updates

    See more
    • Imara to Report Data Demonstrating the Potential of Tovinontrine (IMR-687) for the Treatment of Heart Failure with Preserved Ejection Fraction (HFpEF)

      Preclinical data from three different mouse models of HFpEF to be presented at American Heart Association (AHA) Scientific Sessions HFpEF development to be led by cardiologist Toni Bransford, M.D., FACC, FASE Imara's new Vice President of Clinical Development BOSTON, Nov. 08, 2021 (GLOBE NEWSWIRE) -- Imara Inc. (NASDAQ:IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients suffering from rare inherited genetic disorders of hemoglobin and other serious diseases, announced data today in three preclinical mouse models of heart failure with preserved ejection fraction (HFpEF) treated with tovinontrine (IMR-687). Sele

      11/8/21 7:00:00 AM ET
      $IMRA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Imara Announces Appointment of Laura A. Williams, M.D., MPH to Board of Directors

      BOSTON, June 30, 2021 (GLOBE NEWSWIRE) -- Imara Inc. (NASDAQ:IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients suffering from rare inherited genetic disorders of hemoglobin, today announced the election of Laura A. Williams, M.D., MPH to its Board of Directors. Dr. Williams brings 25 years of early-to-late-stage drug development experience across multiple therapeutic areas, as well as expertise in patient advocacy to Imara. "We're thrilled to welcome Dr. Williams to our Board," said Rahul Ballal, Ph.D., President and Chief Executive Officer of Imara. "In addition to her significant experience leading clinical

      6/30/21 7:00:00 AM ET
      $IMRA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Imara Announces the Appointment of Kenneth Attie, M.D. as Chief Medical Officer

      BOSTON, Jan. 20, 2021 (GLOBE NEWSWIRE) -- Imara Inc. (Nasdaq: IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients suffering from rare inherited genetic disorders of hemoglobin, today announced the appointment of Kenneth Attie, M.D. as Senior Vice President and Chief Medical Officer. Dr. Attie joins Imara with over 30 years of experience within academia and the biopharmaceutical industry, most recently at Acceleron Pharma, Inc. where he led global clinical development efforts that led to the recent FDA and EMA approvals of a new treatment for patients with rare anemias, including beta-thalassemia.  “We are exc

      1/20/21 7:00:00 AM ET
      $IMRA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care